2025-09-19 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the provided data, formatted for clarity.

## Eli Lilly and Co (LLY) Stock Analysis

**Eli Lilly and Co (LLY):** A global pharmaceutical company that develops and markets medicines across a broad range of therapeutic areas.

### 1. Performance vs. S&P 500 (VOO)

*   **LLY Cumulative Return:** 233.21%
*   **VOO Cumulative Return:** 106.00%
*   **Absolute Deviation:** 125.4%
*   **Relative Deviation:** 45.1% (Positioned at the 45.1th percentile relative to its historical deviation range).

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period. The relative deviation suggests that while the outperformance is substantial, it's positioned in the lower half of its historical outperformance range (relative to the S&P 500).

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 10.0%  | 56.3% | -19.0% | 0.0   | 75.7   |
| 2016-2018  | 39.0%  | 58.6% | 21.0%  | -0.1  | 103.7  |
| 2017-2019  | 50.0%  | 58.6% | 20.0%  | 0.3   | 117.8  |
| 2018-2020  | 52.0%  | 58.6% | 33.0%  | 0.1   | 151.4  |
| 2019-2021  | 106.0% | 60.6% | 57.0%  | 0.2   | 247.6  |
| 2020-2022  | 98.0%  | 64.8% | 96.0%  | 0.2   | 328.0  |
| 2021-2023  | 133.0% | 64.8% | 115.0% | 0.3   | 522.6  |
| 2022-2024  | 150.0% | 72.2% | 124.0% | 0.2   | 692.1  |
| 2023-2025  | 86.0%  | 76.8% | 28.0%  | 0.2   | 683.9  |

**Analysis:**

*   **CAGR:**  Strong growth rates, especially in recent years.
*   **MDD:** Significant Maximum Drawdown figures suggest considerable volatility.
*   **Alpha:** Consistently positive Alpha values indicate LLY's ability to generate excess returns compared to its benchmark.  Alpha has increased significantly in recent years.
*   **Beta:** Beta values generally close to 0 suggest the stock's volatility is not strongly correlated with the market.
*   **Cap(B):** Market capitalization has grown substantially, reflecting the company's growth.

### 2. Recent Stock Price Movement

*   **Current Price:** 762.93
*   **Previous Close:** 760.13
*   **Change:** 0.37 (Slight increase)
*   **5-day Moving Average:** 758.27
*   **20-day Moving Average:** 739.30
*   **60-day Moving Average:** 747.40

**Analysis:** The stock price is trading above all three moving averages, indicating a potential short-term and medium-term bullish trend. The most recent price increase is relatively small.

### 3. Market Risk Indicator and Signals

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 67.65 (Approaching overbought territory, typically above 70)
*   **PPO:** 0.5098
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **20-day Relative Deviation Change:** 2.7 (+) (Short-term increase)
*   **Expected Return:** 199.9% (Long-term, vs. S&P 500)

**Analysis:** The low MRI suggests a relatively stable market environment. The RSI approaching 70 could signal a potential pullback. The positive change in relative deviation supports the short-term bullish trend. The very high expected return indicates significant potential for long-term outperformance relative to the S&P 500.  The Hybrid Signal suggests a cautious approach.

### 4. Recent News & Significant Events

*   **Novo Nordisk Pops On 'Significant' Weight Loss For Oral Wegovy:**  This could indirectly impact LLY, as both companies compete in the diabetes and weight management markets.
*   **Novo Nordisk cuts US obesity education team as layoffs begin:** This could signal a shift in Novo Nordisk's strategy, potentially creating opportunities for LLY.
*   **Eli Lilly to Invest $5B in Virginia Plant for Cancer Drugs:** This is a major positive development, demonstrating LLY's commitment to expanding its oncology portfolio.
*   **Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents:** Positive news for LLY's existing diabetes franchise.
*   **Berenberg Upgrades Novo Nordisk (NVO) Amid Renewed Growth Outlook:**  This indicates renewed confidence in a key competitor.

**Analysis:** Recent news is a mixed bag. While LLY is making significant investments in cancer drugs and seeing success in diabetes, developments at Novo Nordisk require monitoring.

#### 4-2. Analyst Opinions

*   **Consensus:** Buy (1.75 on a 1-5 scale)
*   **Target Price:** $884.31 (Average) / $1190 (High) / $650 (Low)

**Analysis:** Analyst sentiment is generally positive, with a consensus "Buy" rating and an average target price significantly above the current price. However, the wide range between high and low target prices suggests some uncertainty.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출     |
|--------------|------|----------|
| 2025-08-07  | 6.3  | 15.56 B$ |
| 2025-05-01  | 3.07 | 12.73 B$ |
| 2024-10-30  | 1.08 | 11.44 B$ |
| 2024-08-08  | 3.29 | 11.30 B$ |
| 2025-08-07  | 3.29 | 11.30 B$ |

**Analysis:**  Recent EPS and revenue figures show a strong upward trend. The most recent quarter (2025-08-07) shows a significant jump in both EPS and Revenue.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30  | $15.56B   | 84.27%        |
| 2025-03-31  | $12.73B   | 82.53%        |
| 2024-12-31  | $13.53B   | 82.24%        |
| 2024-09-30  | $11.44B   | 81.02%        |
| 2024-06-30  | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30  | $18.27B   | 30.98%   |
| 2025-03-31  | $15.76B   | 17.50%   |
| 2024-12-31  | $14.19B   | 31.07%   |
| 2024-09-30  | $14.24B   | 6.81%    |
| 2024-06-30  | $13.56B   | 21.88%   |

**Analysis:**  Revenue and profit margins are consistently high and increasing, demonstrating strong financial performance.  Equity is growing, and ROE is generally strong, indicating efficient capital utilization.

### 7. Overall Summary

Eli Lilly (LLY) demonstrates very strong financial performance and market momentum. Here's a recap:

*   **Outperformance:** LLY has significantly outperformed the S&P 500, though its relative deviation suggests the outperformance is within its historical range.
*   **Growth:** Strong CAGR and positive Alpha confirm consistent growth.
*   **Financial Health:** High and increasing revenue, profit margins, and ROE showcase excellent financial management.
*   **Market Sentiment:** Analyst consensus is a "Buy," with target prices indicating further upside.
*   **Catalysts:** The company's investment in cancer drugs and success in diabetes medications are positive catalysts.
*   **Risks:** High MDD indicates potential volatility. Developments at competitors like Novo Nordisk should be monitored. The RSI is approaching overbought levels, and the Hybrid Signal suggests a cautious approach.
*   **Recommendation:** Based on the data, LLY appears to be a strong investment, particularly for long-term growth. However, investors should be aware of the potential for volatility and competition within the pharmaceutical industry. The current Hybrid Signal suggests considering a more conservative entry point.
